Management Team

Amarpreet Sawhney Ph.D.
President, Chief Executive Officer and Chairman of the Board of Directors
Sawhney
Amarpreet Sawhney, Ph.D., has served as President, Chief Executive Officer and a member of our Board since co-founding the Company in 2006, and he was elected as Chairman of the Board in June 2014. Dr. Sawhney served as CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April
Jim Fortune
Chief Operating Officer
Jim Fortune has more than 25 years of senior operating experience in both public and private companies within the healthcare sector. He joined Ocular Therapeutix in 2008, also serving as Chief Operating Officer of Augmenix from 2008 until April 2014 and as COO of AccessClosure from 2008 to 2010.
Peter Jarrett Ph.D.
Chief Technical Officer
Peter Jarrett, Ph.D., has more than 30 years of R&D experience, ranging from discovery to commercialization. Dr. Jarrett joined Ocular Therapeutix in 2007. Previously, he was Vice President of R&D at Focal, subsequently being named VP of Biomaterials R&D at Genzyme upon the latter company’s
Jonathan Talamo, M.D.
Chief Medical Officer
Jonathan Talamo, M.D., joined Ocular Therapeutix in 2016, bringing more than 25 years of experience as an ophthalmologist, innovator, and clinical investigator. During his career, Dr. Talamo has advised numerous early to late-stage ophthalmology companies and served as an investigator for clinical
Eric Ankerud J.D.
Executive Vice President, Clinical, Regulatory and Quality
Eric Ankerud has more than 25 years of product approval experience covering a wide range of pharmaceuticals, medical devices, and biologics. He joined Ocular Therapeutix in 2007, also serving as Executive Vice President, Clinical, Regulatory and Quality at a sister company Augmenix from 2008 until
Scott Corning
Vice President, Sales and Marketing
Scott Corning brings 15 years of ophthalmic medical device and pharmaceutical marketing experience covering a range of ophthalmic surgical equipment, diagnostic devices and pharmaceuticals. Prior to joining Ocular Therapeutix in 2010, Mr. Corning held marketing management positions at Alcon in both
Art Driscoll
Vice President, Product Development
Art has more than 20 years of biomaterials, medical device and biotech experience in both public and private companies, with a strong record of developing technologies from bench top through commercialization. Prior to joining Ocular Therapeutix in 2011, Mr.